CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 88 enrolled
Drug / intervention
Nateglinide +1 moredrug
Likely dose
Nateglinide 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00858013
NCT00858013Phase 4Completed
CompareCT.gov

Multi-center, Randomized, Open Label Study of the Durability of Glycemic Control With Nateglinide Versus Glimepiride as Monotherapy in Type 2 Diabetic Patients

Ajou University School of Medicine·interventional·Posted Mar 9, 2009·Updated May 16, 2017

In Brief

A Phase 4 clinical trial evaluating Nateglinide and Glimepiride for Type 2 Diabetes Mellitus. Completed, enrolled 88 participants across 7 sites.

Detailed Summary

This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesSouth Korea
CollaboratorsKorea University Guro Hospital, Hanyang University, Inha University Hospital, Kyunghee University Medical Center, Myongji Hospital, Bundang CHA Hospital, Wonju Severance Christian Hospital, Hallym University Medical Center

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 9, 2009
Enrollment StartApr 24, 2009
Primary CompletionJun 25, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.3 years ago

Interventions

Nateglinidedrug

Nateglinide 90\~120mg three times a day

Glimepiridedrug

Glimepiride 1\~2mg once a day